May 13, 2022
May 13, 2022 –
Eli Lilly’s MounjaroTM (tirzepatide) has received FDA approval for use alongside diet and exercise to improve blood sugar control in adults who have type 2 diabetes.
May 12, 2022
May 12, 2022 –
Sandoz has launched the first fully substitutable generic for Genentech’s Esbriet® (pirfenidone) tablets. Esbriet is also available in capsule form
May 12, 2022
May 12, 2022 –
Radicava ORS® (edaravone – Mitsubishi Tanabe Pharma America), has received FDA approval to treat amyotrophic lateral sclerosis (ALS) in adults.
May 11, 2022
May 11, 2022 –
Olumiant® (baricitinib – Eli Lilly and Incyte) is now approved to treat COVID-19 in hospitalized adults who require supplemental oxygen
May 5, 2022
May 5, 2022 –
Due to potential for rare but serious blood clots, the FDA has limited emergency use authorization (EAU) for Janssen’s COVID-19 vaccine.
May 4, 2022
May 4, 2022 –
The U.S. FDA has granted regular approval to Enhertu® (fam-trastuzumab deruxtecan-nxki)
as a treatment for unresectable or metastatic HER2-positive
May 4, 2022
May 4, 2022 –
Phathom Pharmaceuticals’ VoqueznaTM Triple Pack (vonoprazan/amoxicillin/clarithromycin) and VoqueznaTM Double Pack (vonoprazan/amoxicillin) have been approved
May 2, 2022
May 2, 2022 –
Supernus Pharmaceuticals’ Qelbree® (viloxazine extended-release capsules) has received an expanded indication to treat attention deficit hyperactivity